Search

Displaying results 2451 - 2460 of 4438 in total
  1. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones. It is a small molecule designed to act as a pharmacological chaperone that specifically b...

  2. Drug

    Glisoxepide

    go.drugbank.com/drugs/DB01289
    Investigational

    by sulphate. … Glisoxepide uptake could be further inhibited by blockers of the hepatocellular monocarboxylate transporter, by the loop diuretic bumetanide, by 4,4'-diisothiocyano-2,2'-stilbenedisulfonate (DIDS) and

  3. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    It was granted approval by FDA in August 2017 under the market name Kymriah.

  4. Drug

    Calcifediol

    go.drugbank.com/drugs/DB00146
    ApprovedInvestigationalNutraceutical

    The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and no...

  5. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis

  6. Drug

    Nogapendekin alfa

    go.drugbank.com/drugs/DB18740
    ApprovedInvestigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without

  7. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    Trials of this drug have most likely been discontinued by the manufacturer. … It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes.

  8. Drug

    Protocatechualdehyde

    go.drugbank.com/drugs/DB11268
    Approved

    Protocatechualdehyde possesses antiproliferative and pro-apoptotic properties against human breast cancer cells and colorectal cancer cells by reducing the expression of pro-oncogenes β-catenin and cyclin

  9. Drug

    Cenobamate

    go.drugbank.com/drugs/DB06119
    ApprovedInvestigational

    Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.

  10. Drug

    Acenocoumarol

    go.drugbank.com/drugs/DB01418
    ApprovedInvestigational

    Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase. This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, IX and X, and interferes with coagulation.